Cargando…

The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study

INTRODUCTION: Neutrophil elastase (NE) and proteinase 3 (PR3) are novel inflammation biomarkers. We investigated their associations with chronic complications, determinants of biomarker levels and effects of fenofibrate in patients with type 2 diabetes mellitus (T2DM) from Fenofibrate Intervention a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ong, Kwok-Leung, Wu, Liang, Januszewski, Andrzej S, O’Connell, Rachel, Xu, Aimin, Scott, Russell S, Sullivan, David R, Rye, Kerry-Anne, Li, Huating, Ma, Ronald CW, Li, Liping, Gebski, Val, Jenkins, Alicia J, Jia, Weiping, Keech, Anthony C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481737/ https://www.ncbi.nlm.nih.gov/pubmed/34275349 http://dx.doi.org/10.1177/14791641211032547

Ejemplares similares

Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes
por: Januszewski, Andrzej S., et al.
Publicado: (2021)

An Update on the Molecular Actions of Fenofibrate and Its Clinical Effects on Diabetic Retinopathy and Other Microvascular End Points in Patients With Diabetes
por: Noonan, Jonathan E., et al.
Publicado: (2013)

High Density Lipoproteins and Diabetes
por: Cochran, Blake J., et al.
Publicado: (2021)

Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
por: Scott, Russell, et al.
Publicado: (2009)

Limited proteolysis by macrophage elastase inactivates human alpha 1- proteinase inhibitor
Publicado: (1980)

Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment: The FIELD Study
por: Ting, Ru-Dee, et al.
Publicado: (2012)

Improving efficiency of fitting Cox proportional hazards models for time-to-event outcomes in genome-wide association studies (GWAS)
por: Gebski, Val, et al.
Publicado: (2023)

Increased proteinase 3 and neutrophil elastase plasma concentrations are associated with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes
por: Mirea, Andreea-Manuela, et al.
Publicado: (2019)

Potent and Broad but not Unselective Cleavage of Cytokines and Chemokines by Human Neutrophil Elastase and Proteinase 3
por: Fu, Zhirong, et al.
Publicado: (2020)

The human neutrophil serine proteinases, elastase and cathepsin G, can mediate glomerular injury in vivo
Publicado: (1988)

Leukocyte elastase, a1-proteinase inhibitor, and autoantibodies to neuroantigens in diagnostics of endogenous depressive disorders
por: Sarmanova, Z., et al.
Publicado: (2022)

The inhibitory complex of human alpha 1-proteinase inhibitor and human leukocyte elastase is a neutrophil chemoattractant
Publicado: (1988)

Effects of fenofibrate on inflammatory cytokines in diabetic retinopathy patients
por: Ju, Hai-Bing, et al.
Publicado: (2017)

Fenofibrate and Impaired Taste Perception in Type 2 Diabetes
por: Davis, Timothy M.E.
Publicado: (2020)

High Fidelity Processing and Activation of the Human α-Defensin HNP1 Precursor by Neutrophil Elastase and Proteinase 3
por: Tongaonkar, Prasad, et al.
Publicado: (2012)

Diabetic cardiomyopathy: effects of fenofibrate and metformin in an experimental model – the Zucker diabetic rat
por: Forcheron, Fabien, et al.
Publicado: (2009)

Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]
Publicado: (2005)

Effect of fenofibrate on microcirculation and wound healing in healthy and diabetic mice
por: Valentin, S, et al.
Publicado: (2009)

Should We Start All Patients with Diabetic Retinopathy on Fenofibrates?
por: Koshy, Jacob, et al.
Publicado: (2013)

Fenofibrate improves vascular endothelial function and contractility in diabetic mice
por: Xu, Nan, et al.
Publicado: (2018)

Efficacy of fenofibrate for diabetic retinopathy: A systematic review protocol
por: Su, Xing-jie, et al.
Publicado: (2019)

Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia
por: Sun, Xiaomeng, et al.
Publicado: (2020)

Extended Cleavage Specificity of Human Neutrophil Elastase, Human Proteinase 3, and Their Distant Ortholog Clawed Frog PR3—Three Elastases With Similar Primary but Different Extended Specificities and Stability
por: Fu, Zhirong, et al.
Publicado: (2018)

The Plant-Derived Bauhinia bauhinioides Kallikrein Proteinase Inhibitor (rBbKI) Attenuates Elastase-Induced Emphysema in Mice
por: Martins-Olivera, Bruno Tadeu, et al.
Publicado: (2016)

A Plant Proteinase Inhibitor from Enterolobium contortisiliquum Attenuates Pulmonary Mechanics, Inflammation and Remodeling Induced by Elastase in Mice
por: Theodoro-Júnior, Osmar Aparecido, et al.
Publicado: (2017)

Plant Proteinase Inhibitor BbCI Modulates Lung Inflammatory Responses and Mechanic and Remodeling Alterations Induced by Elastase in Mice
por: Almeida-Reis, Rafael, et al.
Publicado: (2017)

Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
por: Rajamani, Kushwin, et al.
Publicado: (2009)

Neutrophil elastase reduces secretion of secretory leukoproteinase inhibitor (SLPI) by lung epithelial cells: role of charge of the proteinase-inhibitor complex
por: Sullivan, Anita L, et al.
Publicado: (2008)

Effects of Fenofibrate on Adiponectin Expression in Retinas of Streptozotocin-Induced Diabetic Rats
por: Hsu, Ying-Jung, et al.
Publicado: (2014)

Reverse Translational Study of Fenofibrate's Observed Effects in Diabetes‐Associated Retinopathy
por: Farris, RA, et al.
Publicado: (2016)

The Role of Akt2 in the Protective Effect of Fenofibrate against Diabetic Nephropathy
por: Cheng, Yanli, et al.
Publicado: (2020)

The Efficacy of Fenofibrate in Addition to Atorvastatin in Patients of Type II Diabetes Mellitus
por: Qasim, Muhammad, et al.
Publicado: (2022)

Effects of Modified Low-Density Lipoproteins and Fenofibrate on an Outer Blood-Retina Barrier Model: Implications for Diabetic Retinopathy
por: Fu, Dongxu, et al.
Publicado: (2020)

Fibroblast growth factor 21 in heart failure
por: Tucker, William, et al.
Publicado: (2022)

The role of secretory leukocyte proteinase inhibitor and elafin (elastase-specific inhibitor/skin-derived antileukoprotease) as alarm antiproteinases in inflammatory lung disease
por: Sallenave, Jean-Michel
Publicado: (2000)

A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations
por: Ling, Hua, et al.
Publicado: (2013)

Pleiotropic Effects of Atorvastatin and Fenofibrate in Metabolic Syndrome and Different Types of Pre-Diabetes
por: Krysiak, Robert, et al.
Publicado: (2010)

Effect of the combination of metformin and fenofibrate on glucose homeostasis in diabetic Goto-Kakizaki rats
por: Oh, Tae Jung, et al.
Publicado: (2013)

Efficiency of fenofibrate in facilitating the reduction of central macular thickness in diabetic macular edema
por: Srinivasan, Srilakshmi, et al.
Publicado: (2018)

Associations of Fenofibrate Therapy With Incidence and Progression of CKD in Patients With Type 2 Diabetes
por: Frazier, Rebecca, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_oj7mdnen6mq2e6ujj6rn6plceo